Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. Co.'s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). Co. owns two patent families directed to STAR-0215. We show 17 historical shares outstanding datapoints in our coverage of ATXS's shares outstanding history.
Understanding the changing numbers of ATXS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ATXS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ATXS by allowing them to research ATXS shares outstanding history
as well as any other stock in our coverage universe. |
Free ATXS Email Alerts:
Video: Shares Outstanding Importance
